The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin (mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and tumor proliferation and plays a significant role in endocrine resistance in breast cancer. Multiple compounds targeting this pathway are being evaluated in clinical trials. These agents are generally well tolerated and can be used in combination with targeted therapies, endocrine therapy or cytotoxic agents. The identification of subtypes of tumors more likely to respond to these therapeutics cannot be overemphasized, since breast cancer is a very heterogeneous malignancy. Activation of pathways such as KRAS and MEK can act as escape mechanisms that lead to resistance, thus a combination of agents targeting multiple steps of the intracellular machinery is promising. There is evidence that tumors with PIK3CA mutations are more sensitive to inhibitors of the PI3K pathway but this has yet to be validated. Large clinical trials with correlative studies are necessary to identify reliable biomarkers of efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“The heterodimer consists of two subunits, with the regulatory subunit (p85) regulating the activation of the catalytic subunit (p110) in response to the absence or presence of upstream stimulation by growth factor receptor tyrosine kinases (RTKs) [Cantley, 2002].”
BackgroundLehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 2×
“Namely, p110α, p110β and p110δ subunits are encoded by PIK3CA, PIK3CB and PIK3CD, while the regulatory subunit is encoded by PIK3R1, PIK3R2, PIK3R3 [Engelman et al.”
BackgroundMaehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427 · cited 1×
“Even though mTORC1 is much better studied and characterized, now it is also believed that mTORC2 is inhibited by these agents in sufficient doses and that it also affects cell metabolism and cancer cell growth (Figure 1) [Sarbassov et al. 2006; Wander et al. 2011].”
BackgroundHu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 412
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Kenerson, H. L., Aicher, L. D., True, L. D., & Yeung, R. S. W. (2002) · PubMed · Cited by 315
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
(2000) · PubMed · Cited by 310
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.559 · Cited by 288
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S.-M., Kwiatkowski, D., & Lane, H. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0668 · Cited by 225
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 208
Andre, F., Campone, M., O'Regan, R., Manlius, C., Massacesi, C., Tarek, S., Mukhopadhyay, P., Soria, J.-C., Naughton, M., & Hurvitz, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8549 · Cited by 207
Self-citationMolecular Profiling for Breast Cancer: A Comprehensive Review
Kittaneh, M., Montero, A. J., & Glück, S. (2013) · Biomarkers in Cancer · doi:10.4137/bic.s9455 · Cited by 190
Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 190
Hong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O'Bryant, C. L., Vo, A. C. H., Klucher, K., Herbst, R. S., Eckhardt, S. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.-A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1141 · Cited by 158
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 158
Jérusalem, G., Fasolo, A., Dieras, V. C., Cardoso, F., Bergh, J. C. S., Vittori, L., Zhang, Y., Massacesi, C., Sahmoud, T., & Gianni, L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1260-x · Cited by 144
Saura, C., Bendell, J. C., Jérusalem, G., Su, S., Ru, Q. C., Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1070 · Cited by 143
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 136
O’Reilly, T., & McSheehy, P. M. J. (2010) · Translational Oncology · doi:10.1593/tlo.09277 · Cited by 133
Rivera, V. M., Squillace, R. M., Miller, D., Berk, L., Wardwell, S. D., Ning, Y., Pollock, R., Narasimhan, N. I., Iuliucci, J. D., Wang, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0792 · Cited by 104
Everolimus: side effect profile and management of toxicities in breast cancer
Paplomata, E., Zelnak, A. B., & O’Regan, R. M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2630-y · Cited by 101
Self-citationAKT-independent PI3-K signaling in cancer – emerging role for SGK3
Hannan, R., Bruhn, Pearson, R., & Sheppard (2013) · Cancer Management and Research · doi:10.2147/cmar.s35178 · Cited by 83
Noh, W. C., Kim, Y. H., Kim, M. S., Koh, J. S., Kim, H., Moon, N. M., & Paik, N.-S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9746-x · Cited by 79
Hurvitz, S. A., Dalenc, F., Campone, M., O’Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2689-5 · Cited by 76
Self-citationPharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Nahta, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320691 · Cited by 76
Phosphoinositide 3‐kinase and INPP4B in human breast cancer
Bertucci, M. C., & Mitchell, C. A. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12036 · Cited by 67
The role of S6K1 in ER-positive breast cancer
Holz, M. K. (2012) · Cell Cycle · doi:10.4161/cc.21194 · Cited by 67
Bowles, D. W., Ma, W. W., Senzer, N., Brahmer, J. R., Adjei, A. A., Davies, M., Lazar, A. J., Vo, A., Peterson, S., Walker, L., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
O'Regan, R. M., Özgüroğlu, M., André, F., Toi, M., Jérusalem, G., Wilks, S. T., Isaacs, C. J., Xu, B., Masuda, N., Arena, F. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.505 · Cited by 58
Self-citationTumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
Juric, D., & Baselga, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6390 · Cited by 43
Piccart, M. J., Noguchi, S., Pritchard, K. I., Burris, H. A., Rugo, H. S., Gnant, M., Hortobágyi, G. N., Melichar, B., Petráková, K., Arena, F. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.559 · Cited by 42
McDonald, G. T., Sullivan, R., Paré, G. C., & Graham, C. H. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.08.007 · Cited by 40
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
O'Regan, R. M., & Paplomata (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30349 · Cited by 30
Self-citationZhang, W., Haines, B. B., Efferson, C. L., Zhu, J. J., Ware, C., Kunii, K., Tammam, J. G., Angagaw, M. H., Hinton, M. C., Keilhack, H., et al. (2012) · Translational Oncology · doi:10.1593/tlo.12241 · Cited by 28
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer
Peddi, P. F., & Hurvitz, S. A. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1369-6 · Cited by 19
Inhibitors of phospholipid intracellular signaling as antiproliferative agents
Powis, G., Hill, S. R., Frew, T., & Sherrill, K. W. (1995) · Medicinal Research Reviews · doi:10.1002/med.2610150204 · Cited by 18
Cited by
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
PI3K/Akt signaling in osteosarcoma
Zhang, J., Yu, X.-H., Yan, Y.-G., Wang, C., & Wang, W.-J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.041 · Cited by 327
Hou, Y., Wang, K., Wan, W., Cheng, Y., Pu, X., & Ye, X. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.06.001 · Cited by 308
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Abdollahzadeh, R., Daraei, A., Mansoori, Y., Sepahvand, M., Amoli, M. M., & Tavakkoly‐Bazzaz, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27941 · Cited by 261
Metadata
- Authors
- Paplomata, E., & O’Regan, R.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2014-04-01
- Volume
- 6
- Issue
- 4
- Pages
- 154-166
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2168133196
- Cited by
- 593
- References
- 71
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.